Sergipe, a state in Brazil, announced the receipt of 7,900 doses of a dengue vaccine manufactured by the Instituto Butantan. The announcement was made by the State Health Secretary on Tuesday, highlighting that the vaccine is quadrivalent, meaning it provides protection against all four serotypes of the dengue virus: 1, 2, 3, and 4. This vaccine is notable for being entirely produced in Brazil, reflecting the country's efforts to enhance its public health initiatives, particularly in combating dengue fever. Initially, the vaccination campaign will target health professionals working in Primary Health Care (Atenção Primária à Saúde or APS). This will include doctors, nurses, surveillance workers, and cleaning teams engaged in the basic health units across the state. This strategic targeting suggests an understanding of the critical role these professionals play in managing public health and highlights the need to equip them first to ensure effective vaccination efforts. According to Illani Paulina, the immunization coordinator for the SES, the vaccination rollout is scheduled to begin next week, following a distribution plan that will account for all 75 municipalities in Sergipe. This planned distribution ensures that the vaccine reaches various regions of the state in an organized manner, aiming to maximize the impact of the vaccination drive against dengue, a disease that poses a significant health risk in tropical regions.